IL-6 involvement in epithelial cancers

Journal of Clinical Investigation

Volumn 117, Issue 12, 2007, Pages 3660-3663

  Schafer, Zachary T ^a   Brugge, Joan S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; INTERLEUKIN 6; JANUS KINASE; NOTCH RECEPTOR; STAT PROTEIN;

BREAST CANCER; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; LUNG ADENOCARCINOMA; LUNG TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STEM CELL;

ANIMALS; ANTIGENS, NEOPLASM; AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CARBONIC ANHYDRASES; CARCINOMA; CELL HYPOXIA; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; JANUS KINASES; LUNG NEOPLASMS; MAMMARY GLANDS, HUMAN; MEMBRANE PROTEINS; MICE; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NOTCH; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; STAT3 TRANSCRIPTION FACTOR; STEM CELLS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 36849017497     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34237     Document Type: Review

References (22)

1. Kishimoto, T. 2005. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23:1-21.
2. Hong, D.S., Angelo, L.S., and Kurzrock, R. 2007. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. doi:10.1002/cncr.22999.
3. Hodge, D.R., Hurt, E.M., and Farrar, W.L. 2005. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer. 41:2502-2512.
4. Chiu, J.J., Sgagias, M.K., and Cowan, K.H. 1996. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin. Cancer Res. 2:215-221.
5. Conze, D., et al. 2001. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 61:8851-8858.
6. Sansone, P., et al. 2007. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117:3988-4002.
7. Gao, S.P., et al. 2007. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117:3846-3856.
8. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100:3983-3988.
9. Sansone, P., et al. 2007. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells. 25:807-815.
10. Dontu, G., et al. 2004. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 6:R605-R615.
11. Paez, J.G., et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497-1500.
12. Hynes, N.E., and Lane, H.A. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer. 5:341-354.
13. Slebos, R.J., and Rodenhuis, S. 1992. The ras gene family in human non-small-cell lung cancer. J. Natl. Cancer Inst. Monogr. 1992:23-29.
14. Ancrile, B., Lim, K.H., and Counter, C.M. 2007. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21:1714-1719.
15. Farnie, G., et al. 2007. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst. 99:616-627.
16. Siziopikou, K.P., and Cobleigh, M. 2007. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 16:104-107.
17. Kim, C.F., et al. 2005. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 121:823-835.
18. Berishaj, M., et al. 2007. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 9:R32.
19. Guo, W., et al. 2006. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 126:489-502.
20. Kamakura, S., et al. 2004. Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. Nat. Cell Biol. 6:547-554.
21. Zaki, M.H., Nemeth, J.A., and Trikha, M. 2004. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer. 111:592-595.
22. Paul-Pletzer, K. 2006. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc). 42:559-576.